Monsanto agreement with Broad for CRISPR system

Monsanto Company announced recently that it has reached a new global licensing agreement with the Broad Institute of MIT and Harvard for the use of the novel CRISPR-Cpf1 genome-editing technology in agriculture.  The CRISPR-Cpf1 system represents an exciting advance in genome-editing technology, because it has potential to be a simpler and more precise tool for making targeted improvements in a cell’s DNA when compared to the CRISPR-Cas9 system.  Researchers believe that the CRISPR-Cpf1 system may offer an expanded set of benefits for advancing and delivering improved agricultural products than the CRISPR-Cas9 system.